Yu. I. Polyakov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yu. I. Polyakov has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Mariia G. Sokolova
Herzen State Pedagogical University of Russia
3 shared publications - Ekaterina V. Lopatina
Pavlov University; Pavlov Institute of Physiology of the Russian Academy of Sciences
2 shared publications - M. A. Privalova
North-Western State Medical University n.a. I. I. Mechnikov; Hospital for War Veterans
2 shared publications Ю. И. Поляков
ФГБОУ ВО «Северо-Западный государственный медицинский университет имени И. И. Мечникова» Минздрава России; ФГБУН «Институт физиологии имени И. П. Павлова» Российской академии наук
2 shared publications- Anna P. Abramova
Almazov National Medical Research Center
1 shared publication - Elena Nikolaeva
Saint Petersburg State University
1 shared publication
Latest Publications
- 19 September 2026
- Published by Springer Nature
- p. 192-205
eGeMAPS-Based Detection of Alzheimer’s Disease in Russian Speech: A Pilot Study
- 19 September 2026
- Published by Springer Nature
- p. 192-205
eGeMAPS-Based Detection of Alzheimer’s Disease in Russian Speech: A Pilot Study
- Open Access
- 27 March 2026
- Published by ECO-Vector LLC (Publications) in Medical academic journal
- Vol. 26 (1) , 5-13
The physiological role of the dystrophin protein and pathological conditions in its deficiency
Dystrophin is a crucial structural rod-shaped protein that stabilizes muscle cell membranes and ensures the normal functioning of skeletal musculature. It is an integral component of the dystrophin-associated glycoprotein complex, which serves as a molecular link connecting the myocyte cytoskeleton to the extracellular matrix. Mutations in the DMD gene, located on the short arm of the X chromosome (Xp21.2), result in the complete or partial loss of dystrophin expression. This deficiency compromises sarcolemmal integrity, leading to uncontrolled calcium influx into the cell, subsequent myocyte destruction, oxidative stress, and chronic inflammation. These pathological cascades are accompanied by progressive necrosis of muscle fibers and their gradual replacement by connective and adipose tissue. The most severe clinical manifestation of dystrophin deficiency is Duchenne muscular dystrophy, an X-linked hereditary neuromuscular disorder with an incidence of approximately one in 3500 to 5000 live male births. The disease is characterized by relentless progression, culminating in the loss of ambulation, respiratory insufficiency, and the development of cardiomyopathy. Current scientific perspectives on dystrophin function extend significantly beyond the mechanical stabilization of muscle tissue. Recent studies indicate that this protein plays a critical role in systemic lipid metabolism and central nervous system activity, thereby elucidating the presence of cognitive disorders and metabolic disturbances in patients. This review provides comprehensive information on the structural organization of dystrophin isoforms, the molecular architecture of the dystrophin-associated protein complex, and a detailed analysis of the pathophysiological processes associated with dystrophin deficiency.
- 27 March 2026
- Published by ECO-Vector LLC (Publications) in Medical academic journal
- Vol. 26 (1) , 5-13
Open AccessThe physiological role of the dystrophin protein and pathological conditions in its deficiency
Dystrophin is a crucial structural rod-shaped protein that stabilizes muscle cell membranes and ensures the normal functioning of skeletal musculature. It is an integral component of the dystrophin-associated glycoprotein complex, which serves as a molecular link connecting the myocyte cytoskeleton to the extracellular matrix. Mutations in the DMD gene, located on the short arm of the X chromosome (Xp21.2), result in the complete or partial loss of dystrophin expression. This deficiency compromises sarcolemmal integrity, leading to uncontrolled calcium influx into the cell, subsequent myocyte destruction, oxidative stress, and chronic inflammation. These pathological cascades are accompanied by progressive necrosis of muscle fibers and their gradual replacement by connective and adipose tissue. The most severe clinical manifestation of dystrophin deficiency is Duchenne muscular dystrophy, an X-linked hereditary neuromuscular disorder with an incidence of approximately one in 3500 to 5000 live male births. The disease is characterized by relentless progression, culminating in the loss of ambulation, respiratory insufficiency, and the development of cardiomyopathy. Current scientific perspectives on dystrophin function extend significantly beyond the mechanical stabilization of muscle tissue. Recent studies indicate that this protein plays a critical role in systemic lipid metabolism and central nervous system activity, thereby elucidating the presence of cognitive disorders and metabolic disturbances in patients. This review provides comprehensive information on the structural organization of dystrophin isoforms, the molecular architecture of the dystrophin-associated protein complex, and a detailed analysis of the pathophysiological processes associated with dystrophin deficiency.
- 26 December 2021
- Published by Alfmed LLC in Medical alphabet
- No. 36,p. 47-51
Retrospective analysis of cerebral neurological complications against background of seasonal respiratory viral infections and new coronavirus infection Covid‑19
Based on the example of seasonal epidemics of respiratory viral infections, it is partially possible to model the outcomes of neurological complications from Covid‑19, taking into account the pathogenetic features of the virus effect on the vascular wall and nerve cells. The accumulated experience of doctors of various specialties makes it possible to prevent such life-threatening complications as ACVA, PATE, intoxication, and sepsis. From the first days of the disease, it is necessary to conduct dynamic monitoring of blood rheology, the level of systemic oxygenation, use anticoagulants in preventive doses in patients at the early stages of the disease, conduct therapy aimed at reducing the risk of cytokine storm development.
- 26 December 2021
- Published by Alfmed LLC in Medical alphabet
- No. 36,p. 47-51
Retrospective analysis of cerebral neurological complications against background of seasonal respiratory viral infections and new coronavirus infection Covid‑19
Based on the example of seasonal epidemics of respiratory viral infections, it is partially possible to model the outcomes of neurological complications from Covid‑19, taking into account the pathogenetic features of the virus effect on the vascular wall and nerve cells. The accumulated experience of doctors of various specialties makes it possible to prevent such life-threatening complications as ACVA, PATE, intoxication, and sepsis. From the first days of the disease, it is necessary to conduct dynamic monitoring of blood rheology, the level of systemic oxygenation, use anticoagulants in preventive doses in patients at the early stages of the disease, conduct therapy aimed at reducing the risk of cytokine storm development.
- 26 December 2021
- Published by Alfmed LLC in Medical alphabet
- No. 36,p. 7-11
Clinical and neurophysiological correlations in post-Covid‑19 patients and rationale for pathogenetic therapy
Clinical and neurological, neurophysiological, and neuropsychological examination of 50 patients aged 50–65 y. o. with an experience of COVID‑19 infection within the last 3 to 6 months, revealed pathological changes in the central nervous system in the form of cerebrastenic and autonomic disorders, motor disorders, vestibulopathy symptoms, which occurred in various combinations, with astheno-vegetative syndrome as obligate. Cognitive impairments were detected in 26% of patients; the mental fatigability index was 1.055 ± 0.124; a high level of situational anxiety was noted in 35% of patients, and a high level of personal anxiety in 50 % of patients with the experience of COVID‑19. The study of brain biopotentials revealed moderate diffuse changes (18%) and irritative disorders on the part of hypothalamic (69 %) and diencephalic structures (20%). All of the above may indicate that, regardless of the form of coronavirus infection occurred in humans, i. e., latent, mild, moderate or severe, one of the targets of the pathological impact of COVID‑19 virus is the median structures of the brain responsible for autonomic and cognitive functions. Nevertheless, in our opinion, these disorders are associated not with a direct pathological effect, but are mediated mainly by circulatory disorders in the microcirculatory bed due to endothelial damage and are rather functional disorders on the part of the central nervous system. This provides the grounds for the selection of pathogenetic therapy aimed at stabilizing the functional state of neurons, and one of the drugs of choice may be citicoline (Noocyl), the action of which is associated with reinforcing the cell membrane of the neuron and normalizing bioelectric processes.
- 26 December 2021
- Published by Alfmed LLC in Medical alphabet
- No. 36,p. 7-11
Clinical and neurophysiological correlations in post-Covid‑19 patients and rationale for pathogenetic therapy
Clinical and neurological, neurophysiological, and neuropsychological examination of 50 patients aged 50–65 y. o. with an experience of COVID‑19 infection within the last 3 to 6 months, revealed pathological changes in the central nervous system in the form of cerebrastenic and autonomic disorders, motor disorders, vestibulopathy symptoms, which occurred in various combinations, with astheno-vegetative syndrome as obligate. Cognitive impairments were detected in 26% of patients; the mental fatigability index was 1.055 ± 0.124; a high level of situational anxiety was noted in 35% of patients, and a high level of personal anxiety in 50 % of patients with the experience of COVID‑19. The study of brain biopotentials revealed moderate diffuse changes (18%) and irritative disorders on the part of hypothalamic (69 %) and diencephalic structures (20%). All of the above may indicate that, regardless of the form of coronavirus infection occurred in humans, i. e., latent, mild, moderate or severe, one of the targets of the pathological impact of COVID‑19 virus is the median structures of the brain responsible for autonomic and cognitive functions. Nevertheless, in our opinion, these disorders are associated not with a direct pathological effect, but are mediated mainly by circulatory disorders in the microcirculatory bed due to endothelial damage and are rather functional disorders on the part of the central nervous system. This provides the grounds for the selection of pathogenetic therapy aimed at stabilizing the functional state of neurons, and one of the drugs of choice may be citicoline (Noocyl), the action of which is associated with reinforcing the cell membrane of the neuron and normalizing bioelectric processes.